Advances in the Therapy of Light Chain Cardiac Amyloidosis

Systemic light chain (AL) amyloidosis stems from abnormal production of amyloidogenic immunoglobulin light chains by plasma cells or B-cell disorders. It can present locally or systemically, with systemic forms posing significant mortality risks, especially if cardiac involvement is present. Delayed diagnosis due to nonspecific symptoms leads to progressive organ dysfunction. Early recognition is vital for timely treatment, aiming to suppress amyloid production and reduce organ damage, thus promoting recovery and improving survival rates. This review article provides a comprehensive overview of the recent advancements in medical therapy for patients with AL cardiac amyloidosis.